# US 2005/0233344 A1 · RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233344 A1
- Document ID: US20050233344A1
- Status: Published application
- Kind: A1
- Application number: 10/923,270
- Filed: 2004-08-20
- Published: 2005-10-20
- Earliest claimed: 2001-05-18
- Assignees: Sirna Therapeutics, Inc.
- Inventors: James McSwiggen; Leonid Beigelman; Bharat Chowrira
- Web page: https://patentgrep.com/patent/US20050233344A1

## CPC

- C07H 21/02: with ribosyl as saccharide radical
- C07K 14/49: Platelet-derived growth factor [PDGF]
- C07K 14/71: for growth factors; for growth regulators
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1132: {against retroviridae, e.g. HIV}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12Y 103/01022: 3-Oxo-5alpha-steroid 4-dehydrogenase (NADP+) (1.3.1.22), i.e. cortisone alpha-reductase
- C12Y 104/03003: D-Amino-acid oxidase (1.4.3.3)
- C12Y 114/19001: Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- C12Y 207/11013: Protein kinase C (2.7.11.13)
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- C12Y 604/01002: Acetyl-CoA carboxylase (6.4.1.2)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/121: Hammerhead
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/318: where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/332: Abasic residue
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/53: partially self-complementary or closed
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/30: chemically synthesised
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to compounds, compositions, and methods useful for modulating platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) genes, such as PDGF and/or PDGFr.

## Claims

### Claim 1

A chemically synthesized double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a PDGFr RNA via RNA interference (RNAi), wherein:
a) each strand of said siNA molecule is about 18 to about 23 nucleotides in length; and
b) one strand of said siNA molecule comprises nucleotide sequence having sufficient complementarity to said PDGFr RNA for the siNA molecule to direct cleavage of the PDGFr RNA via RNA interference.

### Claim 2 (depends on 1)

The siNA molecule of claim 1, wherein said siNA molecule comprises no ribonucleotides.

### Claim 3 (depends on 1)

The siNA molecule of claim 1, wherein said siNA molecule comprises one or more ribonucleotides.

### Claim 4 (depends on 1)

The siNA molecule of claim 1, wherein one strand of said double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence of a PDGFr gene or a portion thereof, and wherein a second strand of said double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or a portion thereof of said PDGFr RNA.

### Claim 5 (depends on 4)

The siNA molecule of claim 4, wherein each strand of the siNA molecule comprises about 18 to about 23 nucleotides, and wherein each strand comprises at least about 19 nucleotides that are complementary to the nucleotides of the other strand.

### Claim 6 (depends on 1)

The siNA molecule of claim 1, wherein said siNA molecule comprises an antisense region comprising a nucleotide sequence that is complementary to a nucleotide sequence of a PDGFr gene or a portion thereof, and wherein said siNA further comprises a sense region, wherein said sense region comprises a nucleotide sequence substantially similar to the nucleotide sequence of said PDGFr gene or a portion thereof.

### Claim 7 (depends on 6)

The siNA molecule of claim 6, wherein said antisense region and said sense region comprise about 18 to about 23 nucleotides, and wherein said antisense region comprises at least about 18 nucleotides that are complementary to nucleotides of the sense region.

### Claim 8 (depends on 1)

The siNA molecule of claim 1, wherein said siNA molecule comprises a sense region and an antisense region, and wherein said antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence of RNA encoded by a PDGFr gene, or a portion thereof, and said sense region comprises a nucleotide sequence that is complementary to said antisense region.

### Claim 9 (depends on 6)

The siNA molecule of claim 6, wherein said siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and a second fragment comprises the antisense region of said siNA molecule.

### Claim 10 (depends on 6)

The siNA molecule of claim 6, wherein said sense region is connected to the antisense region via a linker molecule.

### Claim 11 (depends on 10)

The siNA molecule of claim 10, wherein said linker molecule is a polynucleotide linker.

### Claim 12 (depends on 10)

The siNA molecule of claim 10, wherein said linker molecule is a non-nucleotide linker.

### Claim 13 (depends on 6)

The siNA molecule of claim 6, wherein pyrimidine nucleotides in the sense region are 2′-O-methyl pyrimidine nucleotides.

### Claim 14 (depends on 6)

The siNA molecule of claim 6, wherein purine nucleotides in the sense region are 2′-deoxy purine nucleotides.

### Claim 15 (depends on 6)

The siNA molecule of claim 6, wherein pyrimidine nucleotides present in the sense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides.

### Claim 16 (depends on 9)

The siNA molecule of claim 9, wherein the fragment comprising said sense region includes a terminal cap moiety at a 5′-end, a 3′-end, or both of the 5′ and 3′ ends of the fragment comprising said sense region.

### Claim 17 (depends on 16)

The siNA molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.

### Claim 18 (depends on 6)

The siNA molecule of claim 6, wherein pyrimidine nucleotides of said antisense region are 2′-deoxy-2′-fluoro pyrimidine nucleotides.

### Claim 19 (depends on 6)

The siNA molecule of claim 6, wherein purine nucleotides of said antisense region are 2′-O-methyl purine nucleotides.

### Claim 20 (depends on 6)

The siNA molecule of claim 6, wherein purine nucleotides present in said antisense region comprise 2′-deoxy-purine nucleotides.

### Claim 21 (depends on 18)

The siNA molecule of claim 18, wherein said antisense region comprises a phosphorothioate internucleotide linkage at the 3′ end of said antisense region.

### Claim 22 (depends on 6)

The siNA molecule of claim 6, wherein said antisense region comprises a glyceryl modification at a 3′ end of said antisense region.

### Claim 23 (depends on 9)

The siNA molecule of claim 9, wherein each of the two fragments of said siNA molecule comprise about 21 nucleotides.

### Claim 24 (depends on 23)

The siNA molecule of claim 23, wherein about 19 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule and wherein at least two 3′ terminal nucleotides of each fragment of the siNA molecule are not base-paired to the nucleotides of the other fragment of the siNA molecule.

### Claim 25 (depends on 24)

The siNA molecule of claim 24, wherein each of the two 3′ terminal nucleotides of each fragment of the siNA molecule are 2′-deoxy-pyrimidines.

### Claim 26 (depends on 25)

The siNA molecule of claim 25, wherein said 2′-deoxy-pyrimidine is 2′-deoxy-thymidine.

### Claim 27 (depends on 23)

The siNA molecule of claim 23, wherein all of the about 21 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule.

### Claim 28 (depends on 23)

The siNA molecule of claim 23, wherein about 19 nucleotides of the antisense region are base-paired to the nucleotide sequence of the RNA encoded by a PDGFr gene or a portion thereof.

### Claim 29 (depends on 23)

The siNA molecule of claim 23, wherein about 21 nucleotides of the antisense region are base-paired to the nucleotide sequence of the RNA encoded by a PDGFr gene or a portion thereof.

### Claim 30 (depends on 9)

The siNA molecule of claim 9, wherein a 5′-end of the fragment comprising said antisense region optionally includes a phosphate group.

### Claim 31 (depends on 1)

A composition comprising the siNA molecule of claim 1 in an pharmaceutically acceptable carrier or diluent.

### Claim 32 (depends on 1)

A siNA according to claim 1 wherein the PDGFr RNA comprises Genbank Accession No. NM—002609.2.

### Claim 33 (depends on 1)

A siNA according to claim 1 wherein said siNA comprises any of SEQ ID NOs. 1-744.

### Claim 34 (depends on 32)

A composition comprising the siNA of claim 32 together with a pharmaceutically acceptable carrier or diluent.

### Claim 35 (depends on 33)

A composition comprising the siNA of claim 33 together with a pharmaceutically acceptable carrier or diluent.
